Kiley Juergens Wealth Management LLC Acquires 2,899 Shares of Kenvue Inc. (NYSE:KVUE)

Kiley Juergens Wealth Management LLC grew its holdings in Kenvue Inc. (NYSE:KVUE) by 10.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,485 shares of the company’s stock after purchasing an additional 2,899 shares during the period. Kiley Juergens Wealth Management LLC’s holdings in Kenvue were worth $654,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Planned Solutions Inc. purchased a new position in shares of Kenvue in the 4th quarter worth $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Kenvue during the fourth quarter valued at $28,000. Mather Group LLC. purchased a new position in Kenvue during the first quarter valued at $28,000. CVA Family Office LLC purchased a new position in Kenvue during the fourth quarter valued at $32,000. Finally, Pinnacle Bancorp Inc. lifted its position in Kenvue by 51.3% during the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after purchasing an additional 526 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.1 %

NYSE KVUE traded up $0.02 during trading hours on Wednesday, hitting $18.26. 979,654 shares of the company were exchanged, compared to its average volume of 19,431,836. The stock has a 50-day moving average price of $19.14 and a 200 day moving average price of $19.93. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $17.75 and a 52 week high of $26.25. The stock has a market cap of $34.96 billion, a PE ratio of 23.38, a price-to-earnings-growth ratio of 1.93 and a beta of 1.41.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The business had revenue of $2.89 billion during the quarter, compared to analyst estimates of $3.79 billion. The business’s revenue for the quarter was down 24.9% compared to the same quarter last year. Analysts forecast that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were issued a $0.20 dividend. The ex-dividend date was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.38%. Kenvue’s payout ratio is 102.56%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KVUE shares. William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Citigroup reiterated a “neutral” rating and set a $21.00 target price on shares of Kenvue in a research report on Tuesday, May 28th. Sanford C. Bernstein assumed coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. Finally, HSBC raised their price target on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.